+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Phase 3
Age: 10Years +
All Genders
ID07723963

Randomized Study Evaluating JZP926 Capsules Versus Placebo in Participants Aged 10 and Older With Juvenile Myoclonic Epilepsy

Led by Jazz Pharmaceuticals · Updated on 2026-11-02

260

Participants Needed

23

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of JZP926 capsules for treating Juvenile Myoclonic Epilepsy JME in participants aged 10 years and older. This Phase 23 study is randomized, placebo-controlled, and double-blind, focusing on how well JZP926 reduces the number of days with myoclonic seizures compared to a placebo. The study also examines other effects of JZP926 beyond seizure control. Participants will be randomly assigned to receive either JZP926 capsules or matching placebo capsules based on their body weight. The treatment period lasts 16 weeks, with doses given twice daily. After completing this phase, participants may opt to join an open-label extension of up to 52 weeks, which includes a 4-week blinded transition period, allowing all participants to receive JZP926. During the study, participants will have regular assessments to track seizure frequency and other health measures. This includes monitoring myoclonic seizure days, other seizure types, and patient or caregiver impressions of daily activities. Blood samples will be collected to measure drug and metabolite levels. Safety is monitored throughout, and the primary outcome is the change in myoclonic seizure days over the 16-week treatment. The total study duration may extend up to about 68 weeks for those in the extension phase.

CONDITIONS

Brief Title

A Study to Evaluate the Safety and Efficacy of JZP926 Capsule for the Treatment of Juvenile Myoclonic Epilepsy

Research Team

C

Clinical Trial Disclosure & Transparency

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here